J
Jean Francois H. Geschwind
Researcher at Johns Hopkins University
Publications - 44
Citations - 5909
Jean Francois H. Geschwind is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Transcatheter arterial chemoembolization & Cancer. The author has an hindex of 28, co-authored 44 publications receiving 5235 citations. Previous affiliations of Jean Francois H. Geschwind include Johns Hopkins University School of Medicine & Yale University.
Papers
More filters
Journal ArticleDOI
Transcatheter Treatment of Hepatocellular Carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): Technical Recommendations
Riccardo Lencioni,Thierry de Baere,Marta Burrel,James G. Caridi,Johannes Lammer,Katerina Malagari,Robert C.G. Martin,Elizabeth O’Grady,Maria Isabel Real,Thomas J. Vogl,A. Watkinson,Jean Francois H. Geschwind +11 more
TL;DR: In this paper, a consensus meeting was held to develop a set of technical recommendations for the use of DEBDOX in hepatocellular carcinoma (HCC) treatment and the conclusions of the expert panel are summarized.
Journal ArticleDOI
The Outcome of Liver Transplantation in Patients With Hepatocellular Carcinoma in the United States Between 1988 and 2001: 5-Year Survival Has Improved Significantly With Time
TL;DR: Five-year survival of patients transplanted for HCC is excellent, with a steady improvement in survival over the past decade, and it is possible that the published criteria for patient selection may have contributed to the better outcome.
Journal ArticleDOI
Yttrium-90 Microspheres: Radiation Therapy for Unresectable Liver Cancer
TL;DR: In intraarterial delivery of (90)Y microspheres offers a new alternative in the treatment of unresectable HCC, and the effect on survival is promising.
Journal ArticleDOI
Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis.
TL;DR: Compared with historical control subjects who received traditional forms of treatment, the patients in the present study had extended survival and prospective randomized trials are necessary to show this conclusively and to show which subgroups benefit.
Journal ArticleDOI
The role of functional MR imaging in the assessment of tumor response after chemoembolization in patients with hepatocellular carcinoma.
Ihab R. Kamel,David A. Bluemke,John Eng,Eleni Liapi,Wells A. Messersmith,Diane K. Reyes,Jean Francois H. Geschwind +6 more
TL;DR: In this cohort, diffusion and dynamic contrast medium-enhanced MR imaging parameters were significantly altered after TACE, and these could be useful tools in the assessment of tumor response.